Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
HOME
ISSUES
FOR AUTHORS
CME
Advanced
Search
ORIGINAL ARTICLE
TOOLS
PDF
Save
Download Citation
Article Alert
Slide Set
Reprints
Supplementary
Material
Permissions
Share/Bookmark
Share:
Abstract
Article
References
Letters
Metrics
RELATED ARTICLES
BACKGROUND
Amantadine hydrochloride is one of the most commonly prescribed
medications for patients with prolonged disorders of consciousness
after traumatic brain injury. Preliminary studies have suggested that
amantadine may promote functional recovery.
Full Text of Background...
METHODS
We enrolled 184 patients who were in a vegetative or minimally
conscious state 4 to 16 weeks after traumatic brain injury and who
were receiving inpatient rehabilitation. Patients were randomly
assigned to receive amantadine or placebo for 4 weeks and were
followed for 2 weeks after the treatment was discontinued. The rate of
functional recovery on the Disability Rating Scale (DRS; range, 0 to
29, with higher scores indicating greater disability) was compared
over the 4 weeks of treatment (primary outcome) and during the 2week washout period with the use of mixed-effects regression
models.
Full Text of Methods...
MEDIA IN THIS
ARTICLE
FIGURE 1
TOPICS
MORE IN
Trauma
Head Trauma
Research
March 1, 2012
FIGURE 2
ARTICLE ACTIVITY
124 articles have cited
this article
RESULTS
CORRESPONDENCE
TRENDS
Sign In
CONCLUSIONS
More Trends
Non-invasive Cardiologist
DOVER
Internal Medicine
Hospitalist
OCALA
Nephrology
General Nephrology
COLORADO
Internal Medicine
nejmcareercenter.org
CONTENT: Home
Current Issue
Renew
Articles
Issue Index
Reviewers
Subscribers
Institutions
Pay Bill
Reprints
Product Information
Activate Subscription
Permissions
Conventions
200th Anniversary
Archive 1812-1989
Advertisers
Medical Meetings
Media
Alerts
FAQs
Terms of Use
Purchase Exams
NEJM Knowledge+
Privacy Policy
Copyright
Submit a Manuscript
NEJM Journal Watch
Advertising Policies
Follow us
Copyright 2016 Massachusetts Medical Society. All rights reserved.
Mobile
NEJM Catalyst
NEJM Group
Help
Contact Us